ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för crenolanib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

21 träffar

Bibliografisk träff 2019-07-15

Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.

Weisberg E, Meng C, Case AE, Sattler M, Tiv HL, Gokhale PC, Buhrlage SJ, Liu X, Yang J, Wang J, Gray N, Stone RM, Adamia S, Dubreuil P, Letard S, Griffin JD.

Br J Haematol · comparative study; research-article; journal article · DOI 10.1111/bjh.16092

Bibliografisk träff 2019-07-03

Crenolanib-Derived Probes Suitable for Cell- and Tissue-Based Protein Profiling and Single-Cell Imaging.

Chang Y, Zhu D, Guo H, Yin X, Ding K, Li Z.

Chembiochem · research support, non-u.s. gov't; journal article · DOI 10.1002/cbic.201900067

Bibliografisk träff 2019-06-25

Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression.

Berndsen RH, Castrogiovanni C, Weiss A, Rausch M, Dallinga MG, Miljkovic-Licina M, Klaassen I, Meraldi P, van Beijnum JR, Nowak-Sliwinska P.

Br J Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41416-019-0498-2

Bibliografisk träff 2019-01-16

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.

Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, Lam YL, Sweat R, Follit C, Jain V, Lind E, Borthakur G, Garcia-Manero G, Ravandi F, Kantarjian HM, Cortes J, Collins R, Buelow DR, Baker SD, Druker BJ, Tyner JW.

Nat Commun · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/s41467-018-08263-x

Bibliografisk träff 2018-02-05

CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib.

Jetani H, Garcia-Cadenas I, Nerreter T, Thomas S, Rydzek J, Meijide JB, Bonig H, Herr W, Sierra J, Einsele H, Hudecek M.

Leukemia · research support, non-u.s. gov't; journal article · DOI 10.1038/s41375-018-0009-0

Bibliografisk träff 2017-12-01

The target landscape of clinical kinase drugs.

Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C, Zecha J, Reiter K, Qiao H, Helm D, Koch H, Schoof M, Canevari G, Casale E, Depaolini SR, Feuchtinger A, Wu Z, Schmidt T, Rueckert L, Becker W, Huenges J, Garz AK, Gohlke BO, Zolg DP, Kayser G, Vooder T, Preissner R, Hahne H, Tõnisson N, Kramer K, Götze K, Bassermann F, Schlegl J, Ehrlich HC, Aiche S, Walch A, Greif PA, Schneider S, Felder ER, Ruland J, Médard G, Jeremias I, Spiekermann K, Kuster B.

Science · research support, non-u.s. gov't; research-article; journal article · DOI 10.1126/science.aan4368

Bibliografisk träff 2017-10-16

Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations.

Garz AK, Wolf S, Grath S, Gaidzik V, Habringer S, Vick B, Rudelius M, Ziegenhain C, Herold S, Weickert MT, Smets M, Peschel C, Oostendorp RAJ, Bultmann S, Jeremias I, Thiede C, Döhner K, Keller U, Götze KS.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.21877

Bibliografisk träff 2017-09-21

Effects of crenolanib, a nonselective inhibitor of PDGFR, in a mouse model of transient middle cerebral artery occlusion.

Wang J, Fu X, Zhang D, Yu L, Lu Z, Gao Y, Liu X, Man J, Li S, Li N, Wang M, Liu X, Chen X, Zang W, Yang Q, Wang J.

Neuroscience · research-article; journal article · DOI 10.1016/j.neuroscience.2017.09.025

Bibliografisk träff 2017-08-07

Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia.

Kampa-Schittenhelm KM, Frey J, Haeusser LA, Illing B, Pavlovsky AA, Blumenstock G, Schittenhelm MM.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.19970

Bibliografisk träff 2017-04-19

Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis.

Makino K, Makino T, Stawski L, Mantero JC, Lafyatis R, Simms R, Trojanowska M.

J Invest Dermatol · research-article; journal article · DOI 10.1016/j.jid.2017.03.032

Bibliografisk träff 2015-01-20

The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.

Mathias TJ, Natarajan K, Shukla S, Doshi KA, Singh ZN, Ambudkar SV, Baer MR.

Invest New Drugs · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1007/s10637-015-0205-y

Bibliografisk träff 2014-09-26

Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo.

Wang P, Song L, Ge H, Jin P, Jiang Y, Hu W, Geng N.

Onco Targets Ther · research-article; journal article · DOI 10.2147/ott.s68773

Bibliografisk träff 2014-03-12

Crenolanib is a selective type I pan-FLT3 inhibitor.

Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, Damon LE, Perl AE, Jeschke GR, Sugita M, Carroll M, Kogan SC, Kuriyan J, Shah NP.

Proc Natl Acad Sci U S A · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1073/pnas.1320661111

Bibliografisk träff 2013-11-13

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.

Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, Levis M.

Blood · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1182/blood-2013-10-529313

Bibliografisk träff 2013-11-01

Emergence of crenolanib for FLT3-mutant AML.

Fathi AT.

Blood · comment; journal article · DOI 10.1182/blood-2013-10-528992

Bibliografisk träff 2013-10-16

Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.

Dai J, Kong Y, Si L, Chi Z, Cui C, Sheng X, Mao L, Li S, Lian B, Yang R, Liu S, Xu X, Guo J.

Clin Cancer Res · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-13-1266

Bibliografisk träff 2013-09-17

Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.

Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, Janke LJ, Ramachandran A, Stewart CF, Inaba H, Baker SD.

Blood · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1182/blood-2013-07-513044

Bibliografisk träff 2013-04-11

Determination of crenolanib in human serum and cerebrospinal fluid by liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS).

Roberts MS, Turner DC, Owens TS, Ramachandran A, Wetmore C, Throm SL, Stewart CF.

J Chromatogr B Analyt Technol Biomed Life Sci · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.jchromb.2013.04.002

Bibliografisk träff 2012-06-27

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.

Heinrich MC, Griffith D, McKinley A, Patterson J, Presnell A, Ramachandran A, Debiec-Rychter M.

Clin Cancer Res · research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1158/1078-0432.ccr-12-0625

Bibliografisk träff 2010-10-19

Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor.

Michael M, Vlahovic G, Khamly K, Pierce KJ, Guo F, Olszanski AJ.

Br J Cancer · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1038/sj.bjc.6605941

Bibliografisk träff 2009-09-08

Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers.

Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo F, Pierce KJ, Olszanski AJ, Cohen RB.

J Clin Oncol · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1200/jco.2009.21.8487

Gå till forskningen.

Publikationer i urvalet

Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.

Crenolanib-Derived Probes Suitable for Cell- and Tissue-Based Protein Profiling and Single-Cell Imaging.

Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression.

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.

CAR T-cells targeting FLT3 have potent activity against FLT3<sup>-</sup>ITD<sup>+</sup> AML and act synergistically with the FLT3-inhibitor crenolanib.

The target landscape of clinical kinase drugs.

Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in <i>FLT3</i>-ITD AML with concurrent epigenetic mutations.

Effects of crenolanib, a nonselective inhibitor of PDGFR, in a mouse model of transient middle cerebral artery occlusion.

Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant <i>KIT</i> D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia.

Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis.

The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.

Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo.

Crenolanib is a selective type I pan-FLT3 inhibitor.

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.

Emergence of crenolanib for FLT3-mutant AML.

Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.

Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.

Determination of crenolanib in human serum and cerebrospinal fluid by liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS).

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.

Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor.

Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers.